Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial
Background—We previously reported exogenous anti-factor Xa activity as a pharmacokinetic surrogate marker for edoxaban plasma concentrations. Inhibition of endogenous FXa activity is a more biologically relevant pharmacodynamic measure of edoxaban activity. Here we describe the value of endogenous FXa activity as a pharmacodynamic marker linking edoxaban concentrations and clinical outcomes in the ENGAGE AF-TIMI 48 trial.
Methods—In ENGAGE AF-TIMI 48, edoxaban was administered in higher-dose (HDER, 60/30 mg QD) and lower-dose (LDER, 30/15 mg QD) regimens. Both regimens incorporated a 50% dose reduction in patients with characteristics known to increase edoxaban concentration. Pharmacokinetic-pharmacodynamic modeling was performed in a subgroup of 3029 patients who had samples collected for endogenous FXa activity (measured using an assay after endogenous FX was activated with Russell viper venom).
Results—Endogenous FXa activity decreased with increasing edoxaban concentrations up to 440 ng/mL, indicating that inhibition of endogenous FXa activity is saturated above this concentration threshold. Baseline endogenous FXa activity averaged 92.1±20.9% (relative to normal control samples), and was lower with older age, lower body weight, and in male patients. Model-predicted 24-hour average percentages of inhibition of endogenous FXa activity were 35.8±5.18, 29.1±3.92, 21.9±3.80, and 16.4±2.70 for the HDER 60 mg, dose-reduced HDER 30 mg, LDER 30 mg and dose-reduced LDER 15 mg groups, respectively. A greater average percentage of inhibition of endogenous FXa activity was associated with a lower incidence of ischemic stroke or systemic embolism (IS/SEE) and a higher risk of major bleeding (p<0.001). In a typical subject, the predicted risks for the 10th and 90th percentile of inhibition of endogenous FXa activity were 1.04% and 0.57% for IS/SEE, and 1.35% and 2.33% for major bleeding, respectively.
Conclusions—The extent of inhibition of endogenous FXa activity is influenced by edoxaban dosing and clinical characteristics, and is associated with both antithrombotic benefit and risk of bleeding. This approach of linking endogenous FXa activity to clinical outcomes may be used to guide dose selection in future clinical trials, monitor patients in certain clinical scenarios, or to refine the doses of oral FXa inhibitors in patients who require precise anticoagulation therapy.
Clinical Trial Registration—URL: https://www.clinicaltrials.gov Unique Identifier: NCT00781391.
- Received January 23, 2018.
- Revision received April 30, 2018.
- Accepted June 4, 2018.